Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Claritev’s story has shifted to a more cautious footing, with the top-end fair value ...

DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

CTEV is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of CTEV shares has increased $1.25 since the market last closed. This is a 9.21 ...

The average one-year price target for Claritev (NYSE:CTEV) has been revised to $90.10 / share. This is an increase of 15.22% from the prior estimate of $78.20 dated November 7, 2025. The price target ...

The average one-year price target for Claritev (NYSE:CTEV) has been revised to $66.10 / share. This is a decrease of 26.64% from the prior estimate of $90.10 dated December 18, 2025. The price target ...

Claritev Corp. Annual cash flow by MarketWatch. View CTEV net cash flow, operating cash flow, operating expenses and cash dividends.

An announcement from Claritev ( (CTEV)) is now available. Claritev Corporation disclosed a governance update involving its former Chief Executive Officer and Executive Chair, Dale White, who currently ...

Sept. 30, 2005 — The U.S. Food and Drug Administration (FDA) has approved a rapid test for the differential diagnosis of influenza A and B that is also capable of detecting avian flu isolates; a ...